Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,488.74
(
0.25%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DragonBits

Send PM Follow Ignore
Followers 5
Posts 2508
Boards Moderated 0
Alias Born 02/22/2008

DragonBits

Re: Lewis R Goudy post# 11378

Saturday, 05/31/2008 1:53:13 PM

Saturday, May 31, 2008 1:53:13 PM

Post# of 19309
The correct question would be in theory is there enough of a difference between producing antithrombin Vs FVIII and FIX to make production of antithrombin by PER.C6® cell line impossible or not economically feasible?

One could understand the emphasis on FVIII and FIX since those drugs have a well-established market.

Is there any reason antithrombin couldn't also be produced by this PER.C6® platform?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today